SuperworthNektar Therapeutics shares outstanding NKTR
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 33.1M
- On a year earlier
- +134.6%
- more shares
Nektar Therapeutics had 33.1M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 134.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 20.3M | +45% |
| FY2024 | 14M | +10% |
| FY2023 | 12.7M | +1% |
| FY2022 | 12.5M | +2% |
| FY2021 | 12.3M | +3% |
| FY2020 | 12M | +2% |
| FY2019 | 11.7M | +2% |
| FY2018 | 11.6M | +9% |
| FY2017 | 10.6M | +6% |
| FY2016 | 9.9M | +11% |
| FY2015 | 8.9M | +4% |
| FY2014 | 8.6M | +11% |
| FY2013 | 7.8M | +1% |
| FY2012 | 7.7M | +1% |
| FY2011 | 7.6M | +21% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 33.1M | +135% | |
| Q1 FY26 | 24.7M | +76% | |
| Q4 FY25 | 20.3M | +45% | |
| Q3 FY25 | 18.9M | +36% | |
| Q2 FY25 | 14.1M | +1% | |
| Q1 FY25 | 14.1M | +8% | |
| Q4 FY24 | 14M | +10% | |
| Q3 FY24 | 13.9M | +10% | |
| Q2 FY24 | 13.9M | +10% | |
| Q1 FY24 | 13M | +3% | |
| Q4 FY23 | 12.7M | +1% | |
| Q3 FY23 | 12.7M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Nektar Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.